Department of Vascular Medicine, German Aortic Center, Hamburg, Germany.
Unit of Vascular Surgery, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
Eur J Cardiothorac Surg. 2019 Jul 1;56(1):197-203. doi: 10.1093/ejcts/ezy482.
Thoracic endovascular aortic repair (TEVAR) has emerged as a safe procedure in the treatment of a wide spectrum of descending thoracic aortic pathologies, with satisfactory results both in elective and urgent settings. We investigated the results of our elective, urgent and emergency TEVAR interventions.
A single-centre retrospective analysis of all consecutive patients undergoing TEVAR from 2010 to 2016 was performed. Primary end point of the study was early mortality, whereas the secondary end points included major complications according to the urgency of the procedure. The analysis was further conducted comparing symptomatic, asymptomatic and ruptured cases.
Two hundred and eight patients were treated with TEVAR between January 2010 and April 2016 (mean age 67 ± 12 years, 142 men, 68.3%). Patients undergoing TEVAR as a first-stage procedure for complex thoraco-abdominal repair were excluded. The indication for treatment was a dissection in most cases (n = 92, 44.2%; acute dissection in 40 cases, 19.2%), followed by thoracic aneurysms (n = 64, 30.8%), penetrating aortic ulcers (n = 37, 17.8%), intramural haematomas (n = 8, 3.8%), traumatic ruptures (n = 3, 1.4%) and other indications (n = 4, 1.8%). One hundred and eight procedures were performed electively and 100 urgently. Forty-three patients were treated on an emergency bas for aortic rupture, 44 urgently for thoracic pain and 13 for acute ischaemic complications of aortic dissection or other indications. Ischaemic complications of dissection included 1 case of mesenteric ischaemia, 3 cases of acute renal failure, 4 cases of limb ischaemia and multiple ischaemic complications in 4 cases. Other causes of urgent TEVAR included 1 patient bleeding from a bronchial artery treated with TEVAR after several embolization attempts. In-hospital mortality was 7.7%, significantly higher in the urgent setting (14% vs 1.9%, P = 0.001). Urgent procedures were also more frequently associated with major adverse clinical events (7.4% vs 26%, P = 0.0003) and specifically with paraplegia (2.8% vs 10%, P = 0.043). Perioperative mortality was significantly higher in the ruptured group compared to the symptomatic group (25.6% vs 2.3%, P = 0.002). When the analysis was conducted to compare the symptomatic and the asymptomatic patients, no differences in terms of perioperative mortality were detected.
TEVAR is an effective treatment strategy in thoracic aortic disease. Though emergency repair of the ruptured thoracic aorta still shows high rates of perioperative mortality and morbidity, symptomatic non-ruptured and asymptomatic patients have comparable early outcomes.
胸主动脉腔内修复术(TEVAR)已成为治疗多种降主动脉病变的安全手术,在择期和紧急情况下均取得了满意的效果。我们研究了我们的择期、紧急和急诊 TEVAR 干预的结果。
对 2010 年至 2016 年期间连续接受 TEVAR 治疗的所有患者进行了单中心回顾性分析。研究的主要终点是早期死亡率,次要终点包括根据手术紧急程度的主要并发症。进一步比较了有症状、无症状和破裂的病例。
2010 年 1 月至 2016 年 4 月期间,208 例患者接受 TEVAR 治疗(平均年龄 67±12 岁,142 例男性,68.3%)。排除了作为复杂胸腹修复的第一阶段手术进行 TEVAR 的患者。治疗的指征主要是夹层(n=92,44.2%;急性夹层 40 例,19.2%),其次是胸主动脉瘤(n=64,30.8%)、穿透性主动脉溃疡(n=37,17.8%)、壁内血肿(n=8,3.8%)、创伤性破裂(n=3,1.4%)和其他指征(n=4,1.8%)。108 例手术为择期手术,100 例为紧急手术。43 例因主动脉破裂紧急治疗,44 例因胸痛紧急治疗,13 例因主动脉夹层急性缺血并发症或其他原因紧急治疗。夹层的缺血性并发症包括肠系膜缺血 1 例、急性肾衰竭 3 例、肢体缺血 4 例和 4 例多部位缺血性并发症。紧急 TEVAR 的其他原因包括 1 例支气管动脉出血,经多次栓塞治疗后行 TEVAR 治疗。院内死亡率为 7.7%,紧急情况下明显更高(14% vs 1.9%,P=0.001)。紧急手术也更常发生重大不良临床事件(7.4% vs 26%,P=0.0003),特别是截瘫(2.8% vs 10%,P=0.043)。破裂组的围手术期死亡率明显高于有症状组(25.6% vs 2.3%,P=0.002)。当对有症状和无症状患者进行比较时,围手术期死亡率无差异。
TEVAR 是治疗胸主动脉疾病的有效治疗策略。尽管破裂胸主动脉的紧急修复仍显示出高围手术期死亡率和发病率,但有症状的非破裂和无症状患者具有可比的早期结果。